Levact (Bendamustine Hydrochloride)

Bendamustine forms covalent bonds with DNA, creating interstrand cross‑links that block DNA replication and transcription. This DNA damage activates cell‑cycle checkpoints and triggers programmed cell death, preferentially affecting rapidly dividing malignant lymphocytes.

The dose of Levact is individualized by the prescribing physician based on factors such as disease type, patient weight, renal and hepatic function, and prior treatment history. Specific dosing regimens are determined in the clinical setting and are not disclosed publicly.

Safety of Bendamustine Hydrochloride during pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and the risk of drug transfer through breast milk. Consultation with a specialist is required.

To request Levact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Levact (Bendamustine) belongs to the alkylating agent class, offering a distinct mechanism compared with monoclonal antibodies such as rituximab or other chemotherapy agents like cyclophosphamide. Clinical studies show comparable efficacy in certain lymphoid malignancies, with a different side‑effect profile that may be advantageous in selected patients.

Levact must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

Levact is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, typically over a prescribed period of time, with appropriate monitoring of vital signs and laboratory parameters.

The most serious risks include severe infections due to neutropenia, pulmonary toxicity such as interstitial pneumonitis, and the possible development of secondary malignancies. Prompt recognition of symptoms and regular monitoring are essential to mitigate these risks.

Levact should be avoided in patients with known hypersensitivity to Bendamustine or other nitrogen‑mustard compounds, in those with severe bone‑marrow suppression, and in pregnant or breastfeeding women. Caution is also advised for individuals with significant hepatic or renal impairment.